The Two-Tier Reality of Indian Pharma: Patient Safety, Pharmacovigilance, and the Regulatory Divide
In July 2026, Sun Pharma recalled eleven eye care products after the All India Ophthalmological Society (AIOS) – a body of nearly 27,000 eye specialists – issued a patient safety alert about bacterial contamination consistent with pseudomonas species in certain batches of its Predmet eye drop. The company later expanded the withdrawal, calling it a matter of "abundant precaution".
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
